Dörr Wolfgang
Department of Radiotherapy and Radiooncology, Medical Faculty Carl Gustav Carus, Technical University, Dresden, Germany.
Strahlenther Onkol. 2006 Dec;182(12):693-5. doi: 10.1007/s00066-006-1595-8.
This review summarizes information about modulation of radiation effects in tumor cells and tissues by selenium.
In vitro, clonogenic survival to ionizing radiation was found to be reduced, depending on selenite concentration and duration of administration, by a factor of 1.5-4.4. In experimental animal tumors, a positive effect of selenium was observed with chemotherapy. The only available study in combination with irradiation did not show any benefit of selenium with clinically relevant radiotherapy protocols in R1H tumors. None of the investigations demonstrated a negative effect on the tumor response to therapy.
The only study with fractionated irradiation was performed in a rat R1H tumor, which does not show accelerated repopulation. Therefore, interaction of selenium with such repopulation processes, potentially resulting in increased tumor tolerance, could not be detected. For local administration of normal tissues with selenium, potential tumor effects may be of less importance, but these may be relevant for systemic administration. Therefore, well-designed studies with relevant tumor models and endpoints, and with clinically relevant fractionation protocols are recommended.
本综述总结了有关硒对肿瘤细胞和组织辐射效应调节作用的信息。
在体外，根据亚硒酸盐浓度和给药持续时间，电离辐射后的克隆形成存活率降低了1.5至4.4倍。在实验动物肿瘤中，观察到硒与化疗联合使用具有积极效果。唯一一项与放疗联合的现有研究未显示在R1H肿瘤的临床相关放疗方案中硒有任何益处。没有一项研究表明硒对肿瘤治疗反应有负面影响。
唯一一项关于分次照射的研究是在大鼠R1H肿瘤中进行的，该肿瘤未显示加速再增殖。因此，无法检测到硒与这种再增殖过程的相互作用，而这种相互作用可能导致肿瘤耐受性增加。对于用硒局部给药于正常组织，潜在的肿瘤效应可能不太重要，但对于全身给药可能是相关的。因此，建议采用相关肿瘤模型和终点以及临床相关分次方案进行精心设计的研究。
